SBI-756

News alerts, weekly reports and conference planners

Company:

National Cancer Institute - Bethesda, Sanford-Burnham Medical Research Institute, TGen

Drug class:

AKT inhibitor, mTORC1 inhibitor, NF-κB inhibitor, eIF4G1 inhibitor

NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	SBI-756 Sensitive: D – Preclinical SBI-756 Sensitive : D	SBI-756 Sensitive: D – Preclinical SBI-756 Sensitive : D
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib + SBI-756 Sensitive: D – Preclinical dasatinib + SBI-756 Sensitive : D	dasatinib + SBI-756 Sensitive: D – Preclinical dasatinib + SBI-756 Sensitive : D

Associations
(2)